Alimera Sciences (ALIM) versus Its Competitors Head to Head Review
Alimera Sciences (NASDAQ: ALIM) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it compare to its competitors? We will compare Alimera Sciences to related businesses based on the strength of its analyst recommendations, institutional ownership, risk, dividends, earnings, valuation and profitability.
Volatility & Risk
Alimera Sciences has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Alimera Sciences’ competitors have a beta of 1.18, indicating that their average share price is 18% more volatile than the S&P 500.
Institutional and Insider Ownership
37.2% of Alimera Sciences shares are owned by institutional investors. Comparatively, 44.9% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 14.7% of Alimera Sciences shares are owned by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Alimera Sciences and its competitors revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Alimera Sciences Competitors||$604.20||$110.82||-6.00|
Alimera Sciences’ competitors have higher revenue and earnings than Alimera Sciences. Alimera Sciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Alimera Sciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Alimera Sciences Competitors||-13,405.03%||38.07%||-20.59%|
This is a breakdown of current ratings and target prices for Alimera Sciences and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Alimera Sciences Competitors||121||768||1644||59||2.63|
Alimera Sciences presently has a consensus price target of $4.00, suggesting a potential upside of 205.34%. As a group, “Biopharmaceuticals” companies have a potential upside of 130.10%. Given Alimera Sciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Alimera Sciences is more favorable than its competitors.
Alimera Sciences competitors beat Alimera Sciences on 7 of the 12 factors compared.
About Alimera Sciences
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.